Emerald Bioscience (OTCMKTS:EMBI) Stock Price Up 3.3% – Time to Buy?

Emerald Bioscience Inc. (OTCMKTS:EMBI) was up 3.3% during mid-day trading on Wednesday . The company traded as high as $0.6569 and last traded at $0.6493. 97,306 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 14,236,620 shares. The stock had previously closed at $0.6286.

Emerald Bioscience Stock Up 3.3%

The firm has a 50-day simple moving average of $0.73. The stock has a market cap of $174.06 million, a price-to-earnings ratio of -8.12 and a beta of 0.43. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.43.

About Emerald Bioscience

Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.